Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 11, 2010

BioSystem Development and ProZyme Couple Expertise for Glycan Sample Preparation

  • BioSystem Development and ProZyme are collaborating to develop new methods and systems for glycan analysis. The first product to emerge from the partnership is the GlykoScreen™ Rapid Glycosylation Sample Preparation System (RGSPS). The platform combines ProZyme’s enzymatic N-deglycosylation, labeling, and cleanup chemistry with BioSystem’s AssayMAP™ high-throughput micro chromatography platform.

    In contrast with conventional glycan analysis methods that are labor-intensive, expensive, and take up to three or more days to perform, the new RGSPS platform can process hundreds of samples in under three hours using common laboratory equipment, the firms claim. The system is based on a 96-well SBS-standard format and is suitable for both manual liquid handling and automated workstations. An optional integrated purification module is available for antibody samples.

    The RGSPS system is the first in a family of glycan analysis applications in development using the same platform. “We believe that the products of this partnership will have a profound impact on advancing the field of glycobiology and look forward to leading this initiative,” remarks Jo Wegstein, president of ProZyme.

    BioSystem’s flagship AssayMAP technology has been developed as a new approach to separation-based biomolecule analysis including chromatography, ELISA, and enzymatic digestion. The system hinges on the AssayMAP micro chromatography cartridge, based on a 5 µL packed bed that utilizes a wide range of beaded resins for different applications. AssayMAP has been developed as an open chemistry system that allows the adaptation of existing protocols to the platform without changing validated reagents.

    BioSystem currently offers the AssayMAP technology in the form of complete solutions for analytical requirements in the fields of bioprocess development, biopharmaceutical research, biomarkers, and clinical trial sample analysis. Solutions encompass cartridges prepacked with the appropriate resins, specific reagents as needed, specialized automation hardware (if required), and plug and play protocols including template automation scripts.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »